You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》大和首予諾輝健康(06606.HK)「買入」評級 目標價70元
阿思達克 03-23 12:01
大和發表研究報告,首予諾輝健康(06606.HK)「買入」評級,目標價70元。報告指公司屬內地大腸直腸癌篩查產品市場先驅,受惠核心產品常衛清(ColoClear)優異表現,正邁向行業領導地位。長遠而言,受惠內地癌症篩查市場快速擴張及公司持續研發投入,該行相信公司收入將增加,並擴大渠道至更多特定癌症篩查市場。

報告稱,常衛清作為唯一一款獲國家藥品監督管理局(NMPA)認可大腸直腸癌篩查產品,加上輔助產品噗噗管(Pupu Tube),將快速取得內地直腸癌篩查市場份額。該行料常衛清今年貢獻收入1.2億元人民幣(下同),明年及後年進一步增加至3.3億及7.1億元。

此外,公司受惠於由檢測中心至醫院的產品商業化。屆去年第三季止,諾輝健康覆蓋235家身體檢查中心及316家醫院及診所。報告料非檢查收入佔比將由今年料約67%擴至2024年料佔79%,推高常衛清毛利率由2020年的70%升至2024年82%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account